It has been widely speculated that infections are linked to the development of chronic inflammatory diseases. Although the connection between infection and chronic disease is uncertain, it probably depends on an aberrant immune response. In particular, it is believed that the innate immune system mediates the acute response to an infectious agent 1 , whereas an atypical adaptive immune response may cause chronic inflammation 2 . Furthermore, infection-induced alterations in the adaptive immune response that produce T cell-or antibody-mediated damage to host tissues may underlie the pathogenesis of a variety of common diseases ranging from asthma to diabetes [3] [4] [5] [6] . For example, it has been suggested that common respiratory viruses, such as respiratory syncytial virus (RSV) or human metapneumovirus (hMPV), cause chronic inflammation that leads to asthma 7, 8 . Despite these speculations, it is not known how a chronic disease develops long after the apparent clearance of the inciting infection.
To investigate the possible link between acute viral infection and chronic inflammation, we developed a mouse model of chronic inflammatory lung disease. The infectious agent used in this model is Sendai virus (SeV), which is a mouse parainfluenza virus similar to other paramyxoviruses (for example, RSV, hMPV and human parainfluenza virus) that more commonly infect humans. Mice are relatively resistant to infection with human pathogens such as RSV and hMPV; in contrast, SeV replicates at a high efficiency in the mouse lung, and SeV infection causes injury and inflammation of the small airways (that is, bronchiolitis) that is indistinguishable from the comparable condition in humans. In the C57BL/6 strain of mice, this acute response is followed by a delayed but permanent switch to chronic airway disease that is characterized by mucus production (mucous cell metaplasia) and increased airway reactivity to inhaled methacholine (airway hyperreactivity) [9] [10] [11] . The features of chronic disease manifested in this experimental mouse model are characteristic of human chronic airway diseases such as asthma and COPD. To obtain insight into the pathogenesis of chronic inflammatory disease, we further characterized this distinct mouse model. We identified a new type of innate immune response that drives the development of chronic airway disease. This disease mechanism is therefore distinct from the dogma that the adaptive immune response is solely responsible for chronic inflammatory disease. This unusual immune activity develops after infectious virus is cleared, and the remaining virus in the lung is detectable only by an ultrasensitive PCR-based assay. This new immune axis is of special interest because it provides the first indication, to our knowledge, of how respiratory viral infection is linked to the development of chronic inflammatory disease. Moreover, we show that the immune alterations identified in this mouse model are also present in humans with chronic inflammatory airway disease due to asthma or COPD.
RESULTS

Persistent disease and IL-13-producing macrophages
After wild-type C57BL/6J mice were infected with SeV, chronic disease was manifested by mucous cell metaplasia (with increased lung levels of messenger RNA and immunostaining for the predominant airway mucin Muc5ac) and airway hyperreactivity (with increased pulmonary resistance in response to inhaled methacholine; Fig. 1a and Supplementary Fig. 1 and Supplementary Results online). Evidence of chronic airway disease was first detected on day 21 after inoculation, but disease did not become maximal until day 49 after inoculation ( Fig. 1a and Supplementary Fig. 1 ). Similarly to the time course for appearance of airway disease, interleukin-13 (IL-13) production was first detected on day 21 after inoculation and reached maximal levels on day 49 after inoculation. Furthermore, mice treated with an IL-13 decoy receptor (sIL-13Ra2-Fc) 12, 13 or gene-targeted to be IL-13-deficient (Il13 -/-), no longer developed either mucous cell metaplasia or airway hyperreactivity at any time after viral infection (Fig. 1a, Supplementary Fig. 1 and Supplementary Results). Infectious virus was no longer detectable in the lung by viral plaqueforming assay by day 12 after inoculation 9,11,14 , and SeV-specific RNA expression was decreased to trace levels by day 49 after inoculation, as detected by real-time PCR assay in C57BL/6J wild-type or Il13 -/-mice ( Supplementary Fig. 1 ).
We next investigated the cellular sources of IL-13 in the lung after clearance of infectious virus. At day 21 after inoculation, CD4 + T cells (CD3 + CD4 + ) contributed the highest amount of Il-13 mRNA among immune cells in the lung, but macrophages (Mac1 + CD68 + ) became the predominant cellular source of Il-13 mRNA by day 49 after inoculation of wild-type C57BL/6J mice ( Fig. 1b and Supplementary  Fig. 2 and Supplementary Results online). We also found that lung macrophages cultured from wild-type C57BL/6J mice inoculated with SeV, but not with UV-inactivated virus (SeV-UV), expressed Il-13 mRNA and produced IL-13 protein on day 49 after inoculation ( Fig. 1c and Supplementary Fig. 2 ). IL-13 protein release was further increased by treatment with phorbol myristate acetate (PMA)-ionomycin (Fig. 1c) . Both with and without PMA-ionomycin treatment, IL-13 protein production was increased in lung macrophages compared to CD4 + T cells and in macrophages isolated from SeVinoculated mice compared to macrophages isolated from SeV-UVinoculated control mice (Fig. 1c) . The observed pattern for IL-13 protein production was consistent with the analysis of Il-13 mRNA levels (Fig. 1a,b and Supplementary Fig. 2) . Furthermore, cells with typical macrophage morphology and CD68 expression stained positively for IL-13 after immunostaining of alveolar, interstitial and epithelial locations in wild-type mice, but not in Il13 -/-mice (Fig. 1d,e and data not shown) . Together, these findings provide evidence that lung macrophages are a key cell source of chronic IL-13 production after viral infection. Analysis of macrophage-deficient mice (Csf3 -/-, or op/op, mice) or macrophage-depleted mice (wildtype C57BL/6J mice that were treated with clodronate-containing liposomes) indicated that IL-13 and Muc5ac production after SeV infection depended on the presence of macrophages (Fig. 1f,g and Supplementary Results).
NKT cell requirement for macrophage activation Analysis of major histocompatibility complex (MHC) class IIdeficient H2-Ab1 -/-mice, CD4 -/-or CD8a -/-T cell deficient mice, or mice that were antibody-depleted of CD4 + T cells, CD8 + T cells or both CD4 + and CD8 + T cells showed the usual development of mucous cell metaplasia and IL-13-producing macrophages after viral infection ( Supplementary Fig. 3 and Supplementary Results online). The unexpected findings with T cell blockade led us to investigate whether a previously undescribed type of cellular mechanism could mediate a chronic immune response.
In addition to T cells and macrophages, we found that an increased number of NKT cells were recruited into the lung at day 49 after inoculation ( Fig. 1b, Supplementary Fig. 2 and Supplementary Results). Further analysis of the lung NKT cell population indicated that CD4 -as well as CD4 + NKT cells were a source of Il-13 mRNA in the lung (Fig. 2a-c) . Chronic NKT cell activation after viral infection was marked by a relatively selective increase in Il-13 mRNA production ( Supplementary Fig. 4 online). This pattern of NKT cell activation is distinct from other inflammatory conditions, especially the response to inhaled allergen 15 . Nonetheless, the persistent production of Il-13 mRNA and the accumulation of NKT cells in the lung suggested that this cell population might act in a regulatory role to drive the chronic production of IL-13 by macrophages in the lung. The majority of mouse NKT cells express the semi-invariant Va14-Ja18 T cell receptor (TCR) chain that recognizes glycolipid antigen presented by the nonpolymorphic CD1d, an MHC class I-like protein 16, 17 . Consistent with the involvement of NKT cells in this chronic lung disease, mice that were deficient in NKT cells owing to deletion of the gene encoding Cd1d (Cd1d1 -/-) or the gene encoding the Ja18 component of the invariant TCR (Traj18 -/-) 1, 18 had decreases in the amount of mucous cell metaplasia and airway hyperreactivity as well as the number of IL-13-producing macrophages at day 49 after inoculation ( Fig. 2d-f , Supplementary Fig. 4 and Supplementary Results).
Direct NKT cell-macrophage interaction
On the basis of the findings in NKT cell-deficient mice, we postulated that NKT cells might directly influence the population of IL-13-producing macrophages in the lung after viral infection. In support of a role for NKT cell-dependent recruitment of macrophages, we found that lung macrophage numbers were decreased in NKT celldeficient mice and that purified lung NKT cells produced higher amounts of macrophage chemokines (especially Ccl3) after viral infection ( To determine whether NKT cells might directly stimulate macrophage production of IL-13, we established a system for coculturing purified NKT cells with macrophages. In this system, we found that lung NKT cells induced macrophage production of Il-13 mRNA and protein ( Fig. 3a and Supplementary Results). CD4 + T cells did not have the same effect as NKT cells on macrophage production of IL-13, and the NKT cell effect was inhibited by treatment with monoclonal antibody (mAb) to CD1d, indicating that this NKT cell-macrophage immune axis requires direct contact of TCR Ja18 on the NKT cell with CD1d on the macrophage. Furthermore, NKT cell-dependent activation of lung macrophages was increased by tenfold in the presence of the TCR-CD1d ligand a-GalCer, achieving IL-13 production similar to that achieved by PMA-ionomycin stimulation of macrophages (Fig. 3b) . NKT cell-derived IL-13 was also necessary for NKT celldependent activation of macrophage IL-13 production, as activation was lost when the co-culture was performed with NKT cells from Il13 -/-mice (Fig. 3b) . To determine whether CD4 expression also influenced the NKT cell-macrophage interaction, we studied NKT cells from the liver, which is a more abundant source of CD4 + and CD4 -NKT cells than the lungs. Pure preparations of either CD4 + or CD4 -liver NKT cells provided with CD1d glycolipid ligand were both capable of activating lung macrophages (Fig. 3c) . Thus, although CD4 + NKT cells have been the focus of studies of the response to allergen in the lung 15 , it seems that CD4 expression is not necessary for NKT cell capacity to drive macrophage production of IL-13. Instead, NKT cell-dependent macrophage activation seems to depend primarily on invariant TCR-CD1d and IL-13-IL-13 receptor (IL-13R) interactions.
IL-13R signaling and alternatively activated macrophages
We next examined the downstream events in the NKT cellmacrophage-IL-13 immune axis. Analysis of gene expression in the lungs of wild-type C57BL/6J mice indicated that the only notable postviral change among 148 genes encoding cytokines and cytokine receptors was induction of the gene encoding Il-13 receptor alpha chain (Il13ra1; Supplementary Fig. 6 online) . Induction of IL-13Ra1 expression was driven by NKT cells and was restricted mainly to lung macrophages ( Fig. 4a-c and Supplementary Fig. 7 and Supplementary Results online). Moreover, IL-13-dependent activation of IL-13R was necessary for the development of IL-13-producing macrophages (Fig. 4d,e) .
Further examination of microarray data, followed by real-time PCR and immunostaining, revealed that macrophage production of IL-13 was associated with increased macrophage expression of the Chi3l3, Chi3l4, Fizz1, Arg1, Mmp12 and Alox12e genes (Fig. 4f and Supplementary Fig. 7 ). This pattern of gene expression is characteristic of an alternative pathway of macrophage activation 19, 20 . Like IL-13 production, this type of macrophage activation also depended on NKT cells and IL-13-IL-13R interaction, as it was decreased in Cd1d1 -/-and Il13 -/-mice after viral infection (Fig. 4f-h, Supplementary Fig. 7 and Supplementary Results). Together, these findings imply that increased amounts of macrophage IL-13R could respond to IL-13 produced by NKT cells or macrophages to amplify macrophage production of IL-13 and consequent macrophage activation via the alternative pathway.
NKT cell-macrophage pathway in human chronic airway disease We next determined whether there is evidence of an activated NKT cell-macrophage immune axis in humans with chronic airway disease. On the basis of the established association of acute respiratory viral infection with the subsequent development of chronic asthma, we first investigated whether the NKT cell-macrophage-IL-13 pathway was activated in subjects with asthma. We detected an increased number of macrophages that immunostained positively for IL-13 in bronchoalveolar lavage samples obtained from subjects with severe asthma relative to the number in samples from healthy control subjects ( Supplementary Fig. 8 online) .
To obtain suitable samples of lung tissue for more detailed analysis, we analyzed lung tissue obtained from lung transplant recipients with severe COPD and lung donors who did not have COPD. The lung tissue obtained from subjects with COPD showed marked mucous cell metaplasia as evidenced by an increased number of MUC5AC + mucous cells and higher levels of MUC5AC mRNA in the lung (Fig. 5a,b) . Consistently with our findings in the mouse model of chronic lung disease, we also detected an increased level of IL-13 mRNA in COPD-affected lungs with chronic mucous cell metaplasia (Fig. 5b) . The increase in IL-13 mRNA abundance was associated with an increase in the number of cells that immunostained for IL-13 protein in COPD-affected lung tissue (Fig. 5c) . These IL-13 + cells were identified as lung macrophages on the basis of typical morphology and positive immunostaining for CD68. Furthermore, these IL-13 + CD68 + macrophages were found in increased numbers in lungs from subjects with COPD compared to control subjects without COPD (Fig. 5d) . In addition, we were able to detect NKT cells in lung tissue by immunostaining for the invariant Va24 TCR chain (Fig. 5e ). In concert with larger numbers of mucous cells, increased IL-13 production and larger numbers of IL-13 + macrophages, we also found that Va24 + NKT cells were present in increased numbers in the lungs of subjects with COPD compared to control subjects without COPD (Fig. 5f) . Together, these findings suggest that an innate NKT cell-macrophage-IL-13 immune axis may be activated in human Day 49 p.i.
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DISCUSSION
This report defines a previously undescribed immune pathway for the development of chronic inflammatory lung disease (diagrammed in Fig. 6 ). To identify this pathway, we analyzed an experimental model of chronic airway disease that develops after viral infection. In this model, the inciting virus remains detectable in the lung in trace amounts, and an invariant CD4 -NKT cell population is activated in the lung. This cell population seems to be specially programmed to recruit and activate lung macrophages. Activation of macrophages requires NKT cell production of IL-13 and direct contact between the invariant Va14Ja18-TCR on lung NKT cells and CD1d on macrophages. The activated lung macrophages produce IL-13 and overexpress the IL-13 receptor, and this combination of events establishes a positive feedback loop that promotes the persistent expression of IL-13 as well as of other IL-13-induced genes that are characteristic of an alternative pathway for macrophage activation. The persistent production of IL-13 causes the chronic mucous cell metaplasia and airway hyperreactivity that are characteristic of chronic inflammatory airway diseases such as asthma and COPD. This analysis provides the first evidence, to our knowledge, that IL-13-producing macrophages are present in increased numbers in the lungs of people with asthma and COPD. We also show that an orthologous population of invariant Va24Ja18-TCR NKT cells is found at increased levels in the lung tissue of people with COPD. Together, these findings in this experimental model identify an innate NKT cell-macrophage immune axis that enables a viral infection to initiate a chronic inflammatory lung disease. Analysis of human lung samples obtained from subjects with asthma and COPD indicate that components of this pathway may also contribute to chronic airway diseases that are common in the human population.
Our findings of NKT cell-macrophage function are distinct from previous reports of immune abnormalities in chronic inflammatory disease in general and lung disease in particular. For example, invariant NKT cells were necessary for airway hyperreactivity in a mouse model of allergen-induced asthma and were found in increased numbers in allergic asthma subjects 15, [21] [22] [23] . However, subsequent reports indicated that NKT cells were not necessary for airway inflammation in the mouse model and that the numbers of invariant NKT cells in bronchoalveolar lavage fluid or endobronchial biopsies from either asthma or COPD subjects were no different from the normal numbers 24, 25 . The present approach highlights the usefulness of a more complete assessment of the innate immune response than that done previously. In particular, respiratory viral infection provided a more effective stimulus than acute allergen challenge for chronic activation of the immune system in an experimental mouse model. In addition, a proper assessment of a small subset of lymphocytes was better accomplished with the relatively large amounts of sample tissue that can be obtained from lung resection or transplantation in subjects with airway disease. Finally, a synchronized analysis of the mouse model in combination with human subjects was essential for establishing a previously unrecognized role for NKT cells and IL-13-producing macrophages in the inflammatory process that drives chronic disease.
The presence of a persistent innate immune response suggests that there must be ongoing immune stimulation. However, we did not detect any evidence of infectious virus by 2 weeks after inoculation. But when we used highly sensitive PCR probes and virus-clean isolation rooms, we were able to detect low levels of virus-specific RNA in lung tissue until at least day 49 after inoculation. Whether viral persistence is necessary for a chronic immune response is still being determined. For example, conventional dendritic cells are sites of virus uptake, are activated acutely and perhaps chronically after SeV infection, and are capable of activating NKT cells at low levels of antigen [26] [27] [28] . Our results (like those of others) indicate that invariant NKT cells may also react to CD1d-expressing macrophages by a mechanism that does not require but can be enhanced by high-affinity agonists such as aGalCer 29 . Additional work must therefore be directed at the cause of chronic NKT cell-macrophage activation after viral infection and at the possibility that viral remnants contained in conventional dendritic cells, macrophages or other cell types might drive this process. 
Csf3
-/- Figure 6 Schematic showing an NKT cell-macrophage immune axis leading to chronic airway disease after viral infection. Virus may directly or indirectly facilitate CD1d-dependent antigen presentation and consequent activation of invariant CD4 -NKT cells. NKT cells then interact directly with lung macrophages via contact between invariant Va14 TCR and glycolipid-loaded CD1d. This interaction leads to increased expression of IL-13R and production of IL-13 that drives a positive feedback loop to amplify IL-13 production and alternative activation of macrophages, including induction of Chi3l3, Chi3l4, Fizz1, Mmp12, Arg1 and Alox12e gene expression. Persistent IL-13 production also drives differentiation of airway epithelial cell precursors toward mucous cells (mucous cell metaplasia) and airway smooth muscle cells to become more reactive to contractile agonists (airway hyperreactivity, or AHR).
Our results provide a model for persistent activation of an innate immune axis and present a new paradigm for the pathogenesis of chronic inflammatory lung disease. Previously, immune pathways promoting IL-13 production were viewed primarily as protection against parasitic infection 19, 30 . Infection by extracellular parasites is known to stimulate a T helper type 2 (T H 2) cell response with production of IL-4 and IL-13 that can, in turn, activate macrophages by an alternative pathway 19 . A similar type of response is found after allergen challenge in mice and in allergic asthma in humans 31, 32 . In contrast, intracellular bacteria and viruses characteristically activate a T H 1 response with production of interferon-g and consequent activation of macrophages via the classical pathway. Development of this interferon-dependent pathway is proposed to downregulate the allergic response and protect against allergic airway disease 33 . However, these general patterns were largely defined within the context of an acute immune response 34 . The present observations indicate that viruses can also trigger long-term activation of NKT cells and achieve chronic production of IL-13 by macrophages themselves. In combination with IL-13R signaling, this innate mechanism can establish a state of persistent macrophage activation that is typical of the alternative pathway. Presumably this mechanism evolved to mount a long-term innate immune response independently of CD4 + or CD8 + T cells and thereby enable a response to low-level endemic pathogens that are poorly presented by MHC but adequately presented by CD1d. However, we show that this type of innate immune activation in at least some genetic backgrounds can also lead to the development of chronic inflammatory airway disease in an experimental model and that similar immune activation occurs in subjects with asthma and COPD. Indeed, there is already a well established clinical relationship between acute viral infection and the subsequent development of chronic asthma later in childhood and perhaps adulthood 7 . Other clinical studies will need to be done to test whether people with COPD may share this same link to earlier infection. The present results provide new markers of innate immune activation that can be used to follow how infection leads to chronic inflammatory disease in this group of people and perhaps others.
METHODS
Mouse generation and treatment. We received breeding pairs of Il13 -/-mice from T. Wynn, Cd1d1 -/-mice from A. Bendelac and Traj18 -/-mice from M. Taguchi. We purchased Il4 -/-, op/op (Csf3 -/-) and wild-type C57BL/6J mice from Jackson Laboratory and H2-Ab1 -/-mice from Taconic Farms. All mouse strains were fully backcrossed onto the C57BL/6 background. For IL-13 blockade, we obtained sIL-13Ra2-Fc from S. Goldman and administered this agent at 200 mg/mouse by subcutaneous injection beginning on day 12 after inoculation and then at 3-d intervals. For macrophage depletion, we treated mice with clodronate-containing or control liposomes prepared as described previously 35 . We administered liposomes by intraperitoneal or retro-orbital intravenous injection, using 2 mg at day 14 after inoculation and then 0.5 mg at 3-d intervals thereafter until day 21 or 49 after inoculation, and we monitored macrophage depletion as described previously 35 . We used SeV (Sendai/52, Fushimi strain) to inoculate mice intranasally with virus or ultraviolet light (UV)-inactivated virus as described previously 9, 10, 35, 36 . We delivered SeV at 1 Â 10 5 plaque-forming units per mouse but reduced the inoculum to 0.5 Â 10 5 plaque-forming units for immunocompromised mice (op/op and H2-Ab1 -/-mice) to ensure survival. The Animal Studies Committee of Washington University School of Medicine approved all experimental protocols.
Analysis of mRNA and SeV-specific RNA. We purified RNA from homogenized lung tissue or isolated cells with the RNeasy mini kit (Qiagen), and we made cDNA from RNA with the High-Capacity cDNA Archive kit (Applied Biosystems). We quantified target mRNA and viral RNA levels with real-time PCR using specific fluorogenic probe-primer combinations and Fast Universal PCR Master Mix systems (Applied Biosystems). We performed oligonucleotide microarray analysis as described previously 11, 35 .
Cell isolation and culture. We purified immune cell subsets from lung cell suspensions by FACS using rat, hamster or mouse mAb to mouse cell typespecific protein (BD Biosciences or eBioscience) and a MoFlo high-speed flow cytometer (Dako Cytomation). For macrophage-NKT cell co-culture, we purified macrophages from lung cell suspensions using OptiPrep (SigmaAldrich) followed by adherence to eight-well Lab-Tek II chambers (Nunc). In some experiments, we blocked macrophages with antibody to mouse CD16/ CD32 (1 mg per 1 Â 10 6 cells, BD Biosciences) for 15 min and then incubated them with mAb to CD1d or rat IgG2b control (50 mg/ml, BD Biosciences) for 30 min at 4 1C. We purified lung and liver NKT cells by FACS (after initial enrichment with the MACS Separator (Miltenyi-Biotec)) with FITC-labeled mAb to CD3e plus allophycocyanin-labeled a-GalCer-analog (PBS57)-loaded CD1d tetramer (supplied by the NIH Tetramer Facility) and microbeads specific for allophycocyanin (Miltenyi-Biotec). We cultured macrophages and NKT cells (both 499% purity) at 5 Â 10 4 and 5 Â 10 3 cells per well, respectively, for 24 h at 37 1C in RPMI with 10% FBS (Allanta Biologicals). We collected cell supernatants for ELISA and then washed off NKT cells and lysed adherent macrophages in TRIzol (Invitrogen) for RNA isolation and real-time PCR assay.
Immunohistochemistry. We performed immunostaining with bright-field microscopy as described previously 9, 10, 36 . For immunofluorescence, we used paraffinized sections that were hydrated and incubated in Antigen Unmasking Solution (Vector Labs) for antigen retrieval. We visualized staining with tyramide signal amplification with Alexa Fluor 555 or 594 (Invitrogen). We performed photomicrography and quantification of reporter staining by cell counting (cells per mm of basement membrane or mm 3 of lung tissue) with ImageJ and NIH Image software as described previously 10, 36, 37 .
Human subject samples. We obtained samples from subjects with COPD undergoing lung transplantation and lung donors without COPD as described previously 10 . We performed immunofluorescence microscopy with biotinylated goat mAb to human IL-13 (R&D Systems, 4 mg/ml), biotinylated mouse mAb to human CD68 (clone KP1, DakoCytomation, 5 mg/ml), and mouse mAb to human Va24 (Beckman Coulter, 2 mg/ml) as described above for mouse lung tissue sections. Sections were blocked with 5% goat serum or mouse IgG1 (eBioscience), stained with primary antibody and then with horseradish peroxidase-conjugated secondary antibody to mouse IgG (Invitrogen) or avidin-horseradish peroxidase (Vector ABC Elite System). The Washington University Human Studies Committee approved all human studies, and informed consent was obtained from all human subjects.
Statistical analyses.
We analyzed values for target mRNA, mucous cell and airway reactivity levels using ANOVA for a factorial experimental design. If significance was achieved by one-way analysis, we performed post-ANOVA comparison of means with Scheffe's F-test. We compared PCR data by unpaired Student's t-test. If variances were unequal, we applied Welch's correction. We considered a P value below 0.05 as significant for all analyses. All values represent mean ± s.e.m.
Accession codes. Microarray data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus under series accession number GSE10964.
Note: Supplementary information is available on the Nature Medicine website.
